Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease

doi:10.4292/wjgpt.v16.i1.103898

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1395)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

HTML

764

Tables (1-6)

140

Sum=955

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

131

Download

151

Sum=282

Publishing Process of This Article

Item

Count

Browse

Download

Sum=116

Mar 5, 2025 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898

Table 5 Effectiveness assessment of Happi ER

Effectiveness	Frequency	Percentage
Excellent	619	60.6
Very good	336	32.9
Good	60	5.9
Fair	7	0.7
Total	1022	100.0

Citation: Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898
URL: https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v16.i1.103898